Kura Oncology, Inc.
KURA
$7.58
-$0.07-0.92%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 58.04% | 54.33% | -- | -- | -- |
| Gross Profit | -19.56% | -15.43% | -- | -- | -- |
| SG&A Expenses | 50.92% | 25.58% | 69.17% | 38.30% | 41.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.94% | 44.73% | 63.25% | 40.99% | 41.00% |
| Operating Income | -28.83% | -18.82% | 51.98% | -40.99% | -41.00% |
| Income Before Tax | -30.07% | -15.50% | 59.80% | -40.94% | -36.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.07% | -15.96% | 55.09% | -40.94% | -36.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.07% | -15.96% | 55.09% | -40.94% | -36.75% |
| EBIT | -28.83% | -18.82% | 51.98% | -40.99% | -41.00% |
| EBITDA | -28.90% | -18.89% | 52.20% | -41.22% | -41.25% |
| EPS Basic | -28.65% | -11.30% | 60.14% | -25.19% | -10.18% |
| Normalized Basic EPS | -28.66% | -10.87% | 48.42% | -25.19% | -10.15% |
| EPS Diluted | -28.65% | -11.30% | 60.14% | -25.19% | -10.18% |
| Normalized Diluted EPS | -28.66% | -10.87% | 48.42% | -25.19% | -10.15% |
| Average Basic Shares Outstanding | 1.10% | 4.18% | 12.67% | 12.57% | 24.13% |
| Average Diluted Shares Outstanding | 1.10% | 4.18% | 12.67% | 12.57% | 24.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |